The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Bupropion and Naltrexone in Methamphetamine Use Disorder
Open accessAbstract
BACKGROUND: The use of naltrexone plus bupropion to treat methamphetamine use disorder has not been well studied. METHODS: We conducted this multisite, double-blind, two-stage, placebo-controlled trial with the use of a sequential parallel comparison design to evaluate the efficacy and safety of extended-release injectable naltrexone (380 mg every 3 weeks) plus oral extended-release bupropion (450 mg per day) in adults with moderate or severe methamphetamine use disorder. In the first stage of the trial, participants were randomly assigned in a 0.26:0.74 ratio to receive naltrexone-bupropion or matching injectable and oral placebo for 6 weeks. Those in the placebo group who did not have a response in stage 1 underwent rerandomization in stage 2 and were assigned in a 1:1 ratio to receive naltrexone-bupropion or placebo for an additional 6 weeks. Urine samples were obtained from participants twice weekly. The primary outcome was a response, defined as at least three methamphetamine-negative urine samples out of four samples obtained at the end of stage 1 or stage 2, and the weighted average of the responses in the two stages is reported. The treatment effect was defined as the between-group difference in the overall weighted responses. RESULTS: A total of 403 participants were enrolled in stage 1, and 225 in stage 2. In the first stage, 18 of 109 participants (16.5%) in the naltrexone-bupropion group and 10 of 294 (3.4%) in the placebo group had a response. In the second stage, 13 of 114 (11.4%) in the naltrexone-bupropion group and 2 of 111 (1.8%) in the placebo group had a response. The weighted average response across the two stages was 13.6% with naltrexone-bupropion and 2.5% with placebo, for an overall treatment effect of 11.1 percentage points (Wald z-test statistic, 4.53; P<0.001). Adverse events with naltrexone-bupropion included gastrointestinal disorders, tremor, malaise, hyperhidrosis, and anorexia. Serious adverse events occurred in 8 of 223 participants (3.6%) who received naltrexone-bupropion during the trial. CONCLUSIONS: Among adults with methamphetamine use disorder, the response over a period of 12 weeks among participants who received extended-release injectable naltrexone plus oral extended-release bupropion was low but was higher than that among participants who received placebo. (Funded by the National Institute on Drug Abuse and others; ADAPT-2 ClinicalTrials.gov number, NCT03078075.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Bupropion is contraindicated in individuals with history of seizure or anorexia or bulimia nervosa and should be used with caution in individuals with elevated seizure risk.111”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [111]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three medication studies showed significant reductions in craving ratings for MA: d-amphetamine 60mg/d for four weeks (48), combination of extended release naltrexone (380mg every 3 weeks) and bupropion (450mg q d; (49)) and rTMS (10HZ at left DPLFC, two 5-day sessions over 12 days (42)).”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Lower craving for combination treatment compared to placebo in assessment weeks”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Trivedi, M. et al., 2021
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
Courtney, K. E., & Ray, L. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.08.003 · Cited by 502
Fava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000069738 · Cited by 452
Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings
Panenka, W. J., Procyshyn, R. M., Lecomte, T., MacEwan, G. W., Flynn, S. W., Honer, W. G., & Barr, A. M. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.11.016 · Cited by 432
Twin epidemics: The surging rise of methamphetamine use in chronic opioid users
Ellis, M. S., Kasper, Z. A., & Cicero, T. J. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.08.029 · Cited by 360
Ashok, A. H., Mizuno, Y., Volkow, N. D., & Howes, O. D. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0135 · Cited by 330
Bupropion for the treatment of methamphetamine dependence
Elkashef, A. M., Rawson, R. A., Anderson, A. L., Li, S.-H., Holmes, T., Smith, E. V., Chiang, N., Kahn, R., Vocci, F., Ling, W., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301481 · Cited by 234
Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review
Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00711-x · Cited by 194
Naltrexone for the Treatment of Amphetamine Dependence: A Randomized, Placebo-Controlled Trial
Jayaram-Lindström, N., Hammarberg, A., Beck, O., & Franck, J. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020304 · Cited by 185
Bupropion Reduces Methamphetamine-Induced Subjective Effects and Cue-Induced Craving
Newton, T. F., Roache, J. D., Garza, R. D. L., FONG, T. W., Wallace, C. L., Li, S.-H., Elkashef, A. M., Chiang, N., & Kahn, R. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300979 · Cited by 163
Pharmacotherapy for methamphetamine/amphetamine use disorder—a systematic review and meta‐analysis
Chan, B., Freeman, M., Kondo, K., Ayers, C., Montgomery, J., Paynter, R., & Kansagara, D. (2019) · Addiction · doi:10.1111/add.14755 · Cited by 160
McHugh, R. K., Fitzmaurice, G. M., Carroll, K. M., Griffin, M. L., Hill, K. P., Wasan, A. D., & Weiss, R. D. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.10.002 · Cited by 133
Hendershot, C. S., Wardell, J. D., Samokhvalov, A. V., & Rehm, J. T. (2016) · Addiction Biology · doi:10.1111/adb.12425 · Cited by 96
Pharmacological treatments for methamphetamine addiction: current status and future directions
Ballester, J., Valentine, G. W., & Sofuoglu, M. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1268916 · Cited by 91
Hedegaard, H. B., Bastian, B. A., Trinidad, J. P., Spencer, M. R., & Warner, M. (2019) · PubMed · Cited by 87
Chen, Y., Yang, Y., Hung, H., & Wang, S. (2011) · Contemporary Clinical Trials · doi:10.1016/j.cct.2011.04.006 · Cited by 84
Ray, L. A., Bujarski, S., Courtney, K. E., Moallem, N. R., Lunny, K. F., Roche, D., Leventhal, A. M., SHOPTAW, S. J., Heinzerling, K. G., London, E. D., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.83 · Cited by 79
Self-citationConcise Associated Symptoms Tracking Scale
Trivedi, M. H., Wisniewski, S. R., Morris, D., D, M. F. M., Kurian, B. T., Gollan, J. K., Nierenberg, A. A., Warden, D., Gaynes, B. N., Luther, J. F., et al. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m06840 · Cited by 76
Self-citationAn examination of the efficiency of the sequential parallel design in psychiatric clinical trials
Tamura, R., & Huang, X. (2007) · Clinical Trials · doi:10.1177/1740774507081217 · Cited by 73
Anderson, A. L., Li, S.-H., Markova, D., Holmes, T. H., Chiang, N., Kahn, R., Campbell, J., Dickerson, D. L., Galloway, G. P., Haning, W., et al. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.01.036 · Cited by 70
Heinzerling, K. G., Swanson, A., Hall, T. M., Yi, Y., Wu, Y., & Shoptaw, S. J. (2014) · Addiction · doi:10.1111/add.12636 · Cited by 64
Self-citationNaltrexone: A Pan-Addiction Treatment?
Aboujaoude, E. N., & Salame, W. O. (2016) · CNS Drugs · doi:10.1007/s40263-016-0373-0 · Cited by 64
Doros, G. D., Pencina, M. J., Rybin, D. V., Meisner, A., & D, M. F. M. (2013) · Statistics in Medicine · doi:10.1002/sim.5728 · Cited by 55
Ling, W. W., Farabee, D. J., Liepa, & Wu, L.-T. T. (2012) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s38902 · Cited by 54
Self-citationConcise Associated Symptoms Tracking Scale
(2008) · PsycTESTS Dataset · doi:10.1037/t29353-000 · Cited by 39
Roche, D. J. O., Worley, M. J., Courtney, K. E., Bujarski, S., London, E. D., SHOPTAW, S. J., & Ray, L. A. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4607-8 · Cited by 32
Self-citationPharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups
Soares, E. F. P., & Pereira, F. C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1681970 · Cited by 31
Rúnarsdóttir, V. Á., Hansdóttir, I., Tyrfingsson, Þ., Einarsson, M., Dugosh, K. L., Royer-Malvestuto, C., Pettinati, H. M., Khalsa, J. H., & WOODY, G. E. (2017) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000297 · Cited by 27
Mooney, L. J., Hillhouse, M. P., Thomas, C., Ang, A., Sharma, G., Terry, G., Chang, L., Walker, R., Trivedi, M., Croteau, D., et al. (2016) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000218 · Cited by 25
Self-citationBanks, M. L., Smith, D. A., & Blough, B. E. (2016) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000224 · Cited by 9
Flagged first, then by citations
Cited by
Sorted by citations
The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis
Ciccarone, D. (2021) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000717 · Cited by 987
Kong, X., Liu, C., Zhang, Z., Cheng, M., Mei, Z., Li, X., Liu, P., Diao, L., Ma, Y., Jiang, P., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad926 · Cited by 222
Contingency Management for Patients Receiving Medication for Opioid Use Disorder
Bolívar, H. A., Klemperer, E. M., Coleman, S. R. M., DeSarno, M., Skelly, J. M., & Higgins, S. T. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.1969 · Cited by 190
Jenkins, R. A. (2021) · Preventive Medicine · doi:10.1016/j.ypmed.2021.106541 · Cited by 129
Strong, C., Huang, P.-Y., Li, C., Ku, S. W., Wu, H., & Bourne, A. H. (2022) · The Lancet HIV · doi:10.1016/s2352-3018(22)00124-2 · Cited by 125
Metadata
- Authors
- Trivedi, M. H., Walker, R., Ling, W., dela Cruz, A., Sharma, G., Carmody, T., Ghitza, U. E., Wahle, A., Kim, M., Shores-Wilson, K., Sparenborg, S., Coffin, P., Schmitz, J., Wiest, K., Bart, G., Sonne, S. C., Wakhlu, S., Rush, A. J., Nunes, E. V., & Shoptaw, S.
- Affiliations
- Texas Tech University (US)
- From the Peter O’Donnell Jr. Brain Institute at the University of Texas Southwestern Medical Center (M.H.T.) and the University of Texas Southwestern Medical Center (R.W., A.C., T.C., M.K., K.S.-W., S.W.), Dallas, the University of Texas Health Science Center at Houston, Houston (J.S.), and Texas Tech University, Permian Basin, Odessa (A.J.R.); the University of California, Los Angeles, Los Angeles (W.L., S. Shoptaw); the Emmes Company, Rockville (G.S., A.W.), and the National Institute on Drug...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-01-14
- Volume
- 384
- Issue
- 2
- Pages
- 140-153
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8111570
- OpenAlex
- W3118735640
- Cited by
- 281
- References
- 30
- Citations by year
- 2026: 49 · 2025: 45 · 2024: 45 · 2023: 63 · 2022: 43 · 2021: 35
- FWCI
- 33.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Health and Human Services (Contract No. HHSN271201500065C; HHSN271201400028C)
- National Institute on Drug Abuse (UG1DA020024; UG1DA013035; UG1DA040316; UG1DA013727)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- methamphetamine dependence, naltrexone, bupropion, combination pharmacotherapy, treatment response, adverse events, drug addiction treatment, urine drug testing, relapse prevention, opioid antagonists, antidepressants, stimulant use disorder, treatment efficacy and safety, serious adverse events
- MeSH terms
- Administration, Oral, Adolescent, Adult, Aged, Delayed-Action Preparations, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Injections, Male, Methamphetamine, Middle Aged, Naltrexone, Narcotic Antagonists, Bupropion, Amphetamine-Related Disorders, Medication Adherence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
